Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type! k* N' v$ O, I: B
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 " K" [0 B( Z' V5 t4 u
+ Author Affiliations
) `, U, G8 q* D* n' x9 I4 j3 O) w* e8 r! s/ D
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
$ c4 Y$ s w* V8 p+ Y# s. C* G2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: @' `0 A6 K7 B4 F7 V, n' c& v3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
6 w1 u7 b7 O0 R# g# i4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ' q* \1 C2 d/ x6 v) @' v' R/ a8 {
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, ~+ ?9 U Y/ C9 S( O( `! u5 J: b6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan U2 _. ]3 E8 R2 o2 J: h# Q
7Kinki University School of Medicine, Osaka 589-8511, Japan
v( c/ w! r5 e6 S$ ~1 x8Izumi Municipal Hospital, Osaka 594-0071, Japan
# F7 t5 J- z: \2 Q9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan / K3 ]. v, ^$ H. ]) z. C/ W
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp $ T I c; z9 `% ]
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
$ F- D# v; X9 M4 t' ~7 k! c; \ z5 _' T/ D, q6 p! y
|